TAK-951 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Post Operative Nausea And Vomiting. According to GlobalData, Phase II drugs for Post Operative Nausea And Vomiting have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TAK-951’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TAK-951 is under development for the treatment of post operative nausea and vomiting. It is administered through subcutaneous and intravenous route. The drug candidate acts as a peptide agonist.
Takeda Pharmaceutical overview
Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China, India, and Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
For a complete picture of TAK-951’s drug-specific PTSR and LoA scores, buy the report here.